#1 Clinical Trials Search in Europe

Gsk4381562A

This article discusses the clinical trial of GSK4381562A, a promising drug being studied in combination with other immunotherapies for the treatment of recurrent or metastatic head and neck cancer. The trial aims to evaluate the effectiveness and safety of this new approach compared to existing treatments for patients with PD-L1 positive tumors.

Table of Contents

What is GSK4381562A?

GSK4381562A is a new drug being developed by GlaxoSmithKline for the treatment of certain types of head and neck cancer. It is classified as an immunotherapy, which means it works by helping your body’s own immune system fight cancer cells.[1]

What condition does GSK4381562A target?

GSK4381562A is being studied for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). This is a type of cancer that:

  • Starts in the flat cells lining the mouth, nose, or throat
  • Has either come back after initial treatment (recurrent) or spread to other parts of the body (metastatic)
  • Tests positive for a protein called PD-L1
The cancer may be located in areas such as the oropharynx (back of the throat), oral cavity (mouth), hypopharynx (lower part of the throat), or larynx (voice box).[1]

How does GSK4381562A work?

While the exact mechanism isn’t fully described in the available information, GSK4381562A is likely designed to enhance the body’s immune response against cancer cells. It may work by targeting and blocking proteins that cancer cells use to evade the immune system, such as PD-1 or PD-L1. This allows the immune system to recognize and attack the cancer more effectively.[1]

Current Clinical Trial

GSK4381562A is currently being studied in a Phase 2 clinical trial. This trial is:

  • Randomized: Participants are randomly assigned to different treatment groups
  • Open-label: Both patients and doctors know which treatment is being given
  • Platform study: It uses a master protocol to evaluate multiple treatment combinations
The main goal of this study is to compare the effectiveness of GSK4381562A combined with other immunotherapy drugs to GSK4381562A alone in treating R/M HNSCC.[1]

Who is eligible for the trial?

The trial has specific criteria for who can participate. Some key eligibility factors include:

  • Having confirmed R/M HNSCC that can’t be cured by local treatments
  • No prior systemic therapy for R/M HNSCC
  • Cancer that tests positive for PD-L1
  • Measurable disease based on specific criteria
  • Good overall health status
There are also factors that may exclude someone from participating, such as:
  • Prior treatment with certain types of immunotherapy
  • Active autoimmune diseases
  • Certain other cancers or health conditions
It’s important to note that eligibility is determined by healthcare professionals and trial investigators.[1]

How is GSK4381562A administered?

GSK4381562A is given as a solution for infusion. This means it’s delivered directly into the bloodstream through an intravenous (IV) line. The exact dosing schedule and amount are not specified in the available information and may vary depending on the specific treatment group in the trial.[1]

Potential Benefits

While it’s important to remember that GSK4381562A is still being studied and its effectiveness is not yet proven, potential benefits of this treatment approach may include:

  • Improved ability to fight cancer by enhancing the body’s own immune response
  • Potential for better outcomes compared to existing treatments for R/M HNSCC
  • Possibility of combining with other immunotherapy drugs for enhanced effect
The main goal of the current trial is to measure how well tumors respond to treatment, which will help determine if GSK4381562A is effective against this type of cancer.[1]

Aspect Details
Study Type Phase 2, randomized, open-label, platform study
Drug Studied GSK4381562A (in combination with other immunotherapies)
Condition Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
Primary Objective Evaluate antitumor activity of novel immunotherapy combinations vs. dostarlimab
Primary Endpoint Confirmed Objective Response Rate (ORR)
Key Eligibility Criteria R/M HNSCC, PD-L1 positive, no prior systemic therapy for R/M disease, ECOG PS 0-1
Treatment Duration Up to 24 months

FAQ

  • What type of cancer is being studied in this clinical trial? This clinical trial is studying recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). Specifically, it focuses on cancers in the oropharynx, oral cavity, hypopharynx, and larynx.
  • What is GSK4381562A? GSK4381562A is an investigational drug being studied as part of novel immunotherapy combinations for treating head and neck cancer. It is administered as a solution for infusion through intravenous use.
  • Who is eligible to participate in this clinical trial? Eligible participants must have confirmed HNSCC that is recurrent or metastatic, measurable disease, an ECOG performance status of 0 or 1, and PD-L1 positive tumors. They should not have had prior systemic therapy for recurrent or metastatic disease.
  • What is the main goal of this clinical trial? The main objective of this trial is to evaluate the antitumor activity of novel immunotherapy combinations containing GSK4381562A compared with dostarlimab (another immunotherapy drug) in patients with PD-L1 positive recurrent or metastatic HNSCC.
  • How is the effectiveness of the treatment measured in this trial? The primary measure of effectiveness in this trial is the confirmed objective response rate (ORR). This is defined as the percentage of participants achieving a confirmed complete response (CR) or partial response (PR) according to RECIST 1.1 criteria, as assessed by the investigator.

Ongoing Clinical Trials on Gsk4381562A

  • Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Denmark Finland France Germany Greece Hungary +6

Glossary

  • Squamous Cell Carcinoma of the Head and Neck (HNSCC): A type of cancer that begins in the flat cells that line the inside of the mouth, nose, throat, and voice box.
  • Recurrent/Metastatic (R/M): Cancer that has come back after treatment (recurrent) or has spread to other parts of the body (metastatic).
  • PD-L1: A protein found on some cancer cells that can help them evade the immune system. Drugs targeting PD-L1 can help the immune system recognize and attack cancer cells.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors – a standard way to measure how well a cancer patient responds to treatment.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Dostarlimab: An immunotherapy drug that targets PD-1, a protein on immune cells.
  • HPV: Human Papillomavirus, a virus that can cause certain types of cancer, including some head and neck cancers.

References

  1. http://clinicaltrials.eu/trial/study-of-immunotherapy-combinations-with-dostarlimab-for-patients-with-recurrent-metastatic-pd-l1-positive-head-and-neck-cancer/